Key result
TIGAR inhibition restores glycolysis and rescues impaired angiogenesis in senescent endothelial cells.
Why the study?
Endothelial cells rely on glycolysis for angiogenic functions, and senescence-related p53 induces TIGAR to negatively regulate glycolysis, prompting investigation into the role of the p53-TIGAR axis in senescence-associated endothelial cell dysfunction.
Does genetic or pharmacological inhibition of TIGAR improve glycolytic capacity and restore impaired angiogenic functions in senescent endothelial cells and endothelial cell-specific progeroid mice?
Does genetic or pharmacological inhibition of TIGAR improve glycolytic capacity and restore impaired angiogenic functions in senescent endothelial cells and endothelial cell-specific progeroid mice?
Answers are grounded in this paper and cite their sources.
Inhibiting the p53-TIGAR axis restores glycolytic capacity and reverses senescence-associated impairment of endothelial angiogenesis, offering a potential therapeutic target for ischemic diseases in the elderly.
Background Aging is closely associated with increased morbidity and mortality of various diseases such as cardiovascular diseases. Cellular senescence is primarily involved in aging process. P53, which plays an important role in cellular senescence, regulates energy metabolism by inducing the transcription of TIGAR, a negative regulator of glycolysis. Endothelial cells (ECs) rely on glycolysis for energy production, and glycolysis is closely associated with their angiogenic functions. Purpose We investigated a potential role of the metabolic shift mediated by p53-TIGAR axis in senescence-associated EC dysfunction. Methods/Results Angiogenic capacities, such as migration and tube formation were impaired in senescent ECs. We found that the expression of p53 and TIGAR was substantially increased and that glycolytic capacity was significantly reduced in senescent ECs comparing to those in young cells. Silencing TIGAR recovered glycolytic capacity, and notably improved angiogenic functions in senescent ECs. To analyze the effect of EC senescence on angiogenesis in vivo, we generated mice in which ECs are specifically senescent by overexpressing the dominant negative form of telomere repeat-binding factor 2 using the Tie2-promter. When ischemia-induced angiogenesis was assessed using the hindlimb ischemia model, EC-specific progeroid mice showed worsened blood flow recovery in the ischemic limb compared with wild-type mice. Of note, knockout of TIGAR completely reversed the impaired angiogenesis in EC-specific progeroid mice. These data strongly suggest the therapeutic potential of TIGAR inhibitor in ischemic diseases, especially in elderly people. Therefore, we searched for compounds that inhibit TIGAR. We performed in silico screening using the core library of 9600 compounds selected from the library containing 210 thousand compounds. We identified 271 candidate compounds predicted to bind to the enzymatic active site of TIGAR. Employing a cell-free assay that directly measures TIGAR enzymatic activity, we selected the top 20 compounds with the highest inhibitory activity against TIGAR among them. We chose the top 3 compounds that restored the glycolytic capacity in senescent ECs, assessed by flux analyzer. Finally, we selected a single compound that recovered the impaired migratory and angiogenic capacities in senescent ECs. Now, we are investigating whether continuous administration of this compound via osmotic pump could rescue the impaired ischemia-induced neovascularization in aged mice. Conclusion In the current study, we identified that the senescence-associated metabolic shift mediated through p53–TIGAR axis is critically involved in impaired angiogenic capacities in senescent ECs. Pharmacological inhibition of TIGAR may offer a promising therapeutic strategy for the treatment of ischemic diseases, especially in elderly population.
No takes yet. Share an insight, caveat, or question.
Ito et al. (2026) studied Senescence-associated endothelial dysfunction and hindlimb ischemia. TIGAR silencing, genetic knockout, and pharmacological inhibition (screened from 9,600 compounds) vs. Wild-type mice and untreated senescent or young endothelial cells was evaluated on Glycolytic capacity, angiogenic functions (migration and tube formation), and ischemia-induced blood flow recovery. TIGAR knockout reversed impaired angiogenesis in progeroid mice, and screening 9,600 compounds yielded 1 TIGAR inhibitor that restored glycolysis and angiogenesis in senescent endothelial cells.
Synapse has enriched 10 related papers. Consider them for comparative context: